Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med. 2005;352(4):373–9.
Article
CAS
Google Scholar
Lindner G, Felber R, Schwarz C, Marti G, Leichtle AB, Fiedler GM, et al. Hypercalcemia in the ED: prevalence, etiology, and outcome. Am J Emerg Med. 2013;31(4):657–60.
Article
Google Scholar
Burt ME, Brennan MF. Incidence of hypercalcemia and malignant neoplasm. Arch Surg. 1980;115(6):704–7.
Article
CAS
Google Scholar
Vassilopoulou-Sellin R, Newman BM, Taylor SH, Guinee VF. Incidence of hypercalcemia in patients with malignancy referred to a comprehensive cancer center. Cancer. 1993;71(4):1309–12.
Article
CAS
Google Scholar
Mundy GR, Edwards JR. PTH-related peptide (PTHrP) in hypercalcemia. J Am Soc Nephrol. 2008;19(4):672–5.
Article
CAS
Google Scholar
Mirrakhimov AE. Hypercalcemia of malignancy: an update on pathogenesis and management. N Am J Med Sci. 2015;7(11):483–93.
Article
Google Scholar
Seymour JF, Gagel RF. Calcitriol: the major humoral mediator of hypercalcemia in Hodgkin's disease and non-Hodgkin's lymphomas. Blood. 1993;82(5):1383–94.
Article
CAS
Google Scholar
Mudde AH, van den Berg H, Boshuis PG, Breedveld FC, Markusse HM, Kluin PM, et al. Ectopic production of 1,25-dihydroxyvitamin D by B-cell lymphoma as a cause of hypercalcemia. Cancer. 1987;59(9):1543–6.
Article
CAS
Google Scholar
Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann Oncol. 1999;10(Suppl 2):S31–8.
Article
Google Scholar
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27(3):273–82.
Article
CAS
Google Scholar
Wild D, Mäcke HR, Waser B, Reubi JC, Ginj M, Rasch H, et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur J Nucl Med Mol Imaging. 2005;32(6):724.
Article
Google Scholar
Pauwels E, Cleeren F, Bormans G, Deroose CM. Somatostatin receptor PET ligands - the next generation for clinical practice. Am J Nucl Med Mol Imaging. 2018;8(5):311–31.
CAS
PubMed
PubMed Central
Google Scholar
Deroose CM, Hindié E, Kebebew E, Goichot B, Pacak K, Taïeb D, et al. Molecular imaging of Gastroenteropancreatic neuroendocrine tumors: current status and future directions. J Nucl Med. 2016;57(12):1949–56.
Article
CAS
Google Scholar
Hicks RJ, Kwekkeboom DJ, Krenning E, Bodei L, Grozinsky-Glasberg S, Arnold R, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Neoplasia: peptide receptor radionuclide therapy with radiolabeled Somatostatin analogues. Neuroendocrinology. 2017;105(3):295–309.
Article
CAS
Google Scholar
Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of. N Engl J Med. 2017;376(2):125–35.
Article
CAS
Google Scholar
Clift AK, Kidd M, Bodei L, Toumpanakis C, Baum RP, Oberg K, et al. Neuroendocrine Neoplasms of the Small Bowel and Pancreas. Neuroendocrinology. 2020;110(6):444–76.
van Schaik E, van Vliet EI, Feelders RA, Krenning EP, Khan S, Kamp K, et al. Improved control of severe hypoglycemia in patients with malignant insulinomas by peptide receptor radionuclide therapy. J Clin Endocrinol Metab. 2011;96(11):3381–9.
Article
Google Scholar
Makis W, McCann K, Riauka TA, McEwan AJ. Ectopic Corticotropin-producing neuroendocrine tumor of the pancreas treated with 177Lu DOTATATE induction and maintenance peptide receptor radionuclide therapy. Clin Nucl Med. 2016;41(1):50–2.
Article
Google Scholar
Makis W, McCann K, Riauka TA, McEwan AJ. Glucagonoma pancreatic neuroendocrine tumor treated with 177Lu DOTATATE induction and maintenance peptide receptor radionuclide therapy. Clin Nucl Med. 2015;40(11):877–9.
Article
Google Scholar
Grozinsky-Glasberg S, Barak D, Fraenkel M, Walter MA, Müeller-Brand J, Eckstein J, et al. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer. 2011;117(7):1377–85.
Article
CAS
Google Scholar
Zandee WT, Brabander T, Blažević A, Kam BLR, Teunissen JJM, Feelders RA, et al. Symptomatic and radiological response to 177Lu-DOTATATE for the treatment of functioning pancreatic neuroendocrine tumors. J Clin Endocrinol Metab. 2019;104(4):1336–44.
Article
Google Scholar
Ranade R, Basu S. Metabolic bone disease in the context of metastatic neuroendocrine tumor: differentiation from skeletal metastasis, the molecular PET-CT imaging features, and exploring the possible Etiopathologies including parathyroid adenoma (MEN1) and Paraneoplastic Humoral Hypercalcemia of malignancy due to PTHrP Hypersecretion. World J Nucl Med. 2017;16(1):62–7.
Article
Google Scholar
Kwekkeboom DJ, Krenning EP. Somatostatin receptor imaging. Semin Nucl Med. 2002;32(2):84–91.
Article
Google Scholar
Ezziddin S, Adler L, Sabet A, Pöppel TD, Grabellus F, Yüce A, et al. Prognostic stratification of metastatic gastroenteropancreatic neuroendocrine neoplasms by 18F-FDG PET: feasibility of a metabolic grading system. J Nucl Med. 2014;55(8):1260–6.
Article
CAS
Google Scholar
Zhu V, de Las MA, Janicek M, Hartshorn K. Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D. J Gastrointest Oncol. 2014;5(4):E84–7.
PubMed
PubMed Central
Google Scholar
van Lierop AH, Bisschop PH, Boelen A, van Eeden S, Engelman AF, Nieveen van Dijkum EJ, et al. Hypercalcaemia due to a calcitriol-producing neuroendocrine tumour. J Surg Case Rep. 2019;2019(12):rjz346.
Article
Google Scholar
Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res. 2010;16(3):978–85.
Article
CAS
Google Scholar
Chan DL, Pavlakis N, Schembri GP, Bernard EJ, Hsiao E, Hayes A, et al. Dual Somatostatin receptor/FDG PET/CT imaging in metastatic neuroendocrine Tumours: proposal for a novel grading scheme with prognostic significance. Theranostics. 2017;7(5):1149–58.
Article
CAS
Google Scholar